Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement
| Autor: | Abdelhakim Allali, Nili Schamroth Pravda, Mohamed Abdel-Wahab, Didier Champagnac, Matti Adam, Albert W. Chan, Alessandro Iadanza, John G. Webb, Henrique Barbosa Ribeiro, Claudia Fiorina, David Hildick-Smith, Brian Whisenant, Harindra C. Wijeysundera, Thomas Pilgrim, Lars Søndergaard, Sabine Bleiziffer, Danny Dvir, Gaetan Charbonnier, Giuseppe Bruschi, Cristina Giannini, Marco Barbanti, Anna Sonia Petronio, Björn Redfors, Stéphane Noble, Jasmin Shamekhi, Andrew Chatfield, Alberto Alperi, Jörg Kempfert, Didier Tchetche, Won-Keun Kim, Matheus Simonato, Roberto Nerla, Timm Ubben, Marco Agrifoglio, Matteo Montorfano, Moritz Seiffert, Francesco Saia, Magdalena Erlebach, Hafid Amrane, Luca Testa, Massimo Napodano, Lars Oliver Conzelmann, Josep Rodés-Cabau, Christina Brinkmann, Azeem Latib, Ran Kornowski, Henrik Nissen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Incidence (epidemiology) medicine.medical_treatment Hazard ratio Odds ratio 030204 cardiovascular system & hematology Right bundle branch block Balloon medicine.disease Confidence interval 03 medical and health sciences 0302 clinical medicine Valve replacement Interquartile range Internal medicine Cardiology Medicine 030212 general & internal medicine Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of the American College of Cardiology. 77:2263-2273 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2021.03.228 |
| Popis: | Background Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). Objectives The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. Methods Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. Results A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). Conclusions In a contemporary large series of ViV-TAVR patients, the rate of periprocedural PPI was relatively low, and its incidence decreased with the use of new-generation THV systems. PPI following ViV-TAVR was associated with a trend toward increased mortality at follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|